Trial Profile
Phase I/II Trails of NKT Cell in Combination With Gefitinib For Non Small Cell Lung Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Natural killer cell therapy
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Jul 2021 trial design published in the BMC Cancer
- 23 Nov 2017 New trial record
- 09 Sep 2017 protocol was amended